Clinical outcomes of the proximal optimisation technique (POT) in bifurcation stenting.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
03 Dec 2021
Historique:
pubmed: 11 5 2021
medline: 15 12 2021
entrez: 10 5 2021
Statut: epublish

Résumé

Optimal deployment of coronary stents in a bifurcation lesion remains a matter of debate. We sought to capture the daily practice of bifurcation stenting by means of a worldwide registry and to investigate how post-implantation deployment techniques influence clinical outcomes. Data from the e-ULTIMASTER registry were used to perform an analysis of 4,395 patients undergoing percutaneous coronary intervention for bifurcation lesions. Inverse probability of treatment weights (IPTW) propensity score methodology was used to adjust for any baseline differences. The primary outcome of interest was target lesion failure (TLF) at one year (follow-up rate 96.2%). The global one-year TLF rate was low (5.1%). The proximal optimisation technique (POT) was used in 33.9% of cases and was associated with a reduction in the adjusted TLF rate (4.0% [95% confidence interval: 3.0-5.1%] vs 6.0% [5.1-6.9%], p<0.01) due to a reduction of all components of this composite endpoint, except for cardiac death. Stent thrombosis was also positively impacted (0.4% [0.04-0.7%] vs 1.3% [0.8-1.7%], p<0.01). POT benefit was uniform across subgroups. Conversely, the use of the kissing balloon technique (36.5%) did not influence the adjusted TLF rate. Despite a low one-year failure rate in this large bifurcation stenting cohort, POT was associated with a further reduction in the event rate and a uniform benefit across subgroups, suggesting systematic use of this deployment technique regardless of the bifurcation anatomy and stenting technique.

Sections du résumé

BACKGROUND BACKGROUND
Optimal deployment of coronary stents in a bifurcation lesion remains a matter of debate.
AIMS OBJECTIVE
We sought to capture the daily practice of bifurcation stenting by means of a worldwide registry and to investigate how post-implantation deployment techniques influence clinical outcomes.
METHODS METHODS
Data from the e-ULTIMASTER registry were used to perform an analysis of 4,395 patients undergoing percutaneous coronary intervention for bifurcation lesions. Inverse probability of treatment weights (IPTW) propensity score methodology was used to adjust for any baseline differences. The primary outcome of interest was target lesion failure (TLF) at one year (follow-up rate 96.2%).
RESULTS RESULTS
The global one-year TLF rate was low (5.1%). The proximal optimisation technique (POT) was used in 33.9% of cases and was associated with a reduction in the adjusted TLF rate (4.0% [95% confidence interval: 3.0-5.1%] vs 6.0% [5.1-6.9%], p<0.01) due to a reduction of all components of this composite endpoint, except for cardiac death. Stent thrombosis was also positively impacted (0.4% [0.04-0.7%] vs 1.3% [0.8-1.7%], p<0.01). POT benefit was uniform across subgroups. Conversely, the use of the kissing balloon technique (36.5%) did not influence the adjusted TLF rate.
CONCLUSIONS CONCLUSIONS
Despite a low one-year failure rate in this large bifurcation stenting cohort, POT was associated with a further reduction in the event rate and a uniform benefit across subgroups, suggesting systematic use of this deployment technique regardless of the bifurcation anatomy and stenting technique.

Identifiants

pubmed: 33970107
pii: EIJ-D-20-01393
doi: 10.4244/EIJ-D-20-01393
pmc: PMC9724857
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e910-e918

Références

Int J Mol Sci. 2016 Sep 06;17(9):
pubmed: 27608017
Cardiovasc Revasc Med. 2016 Dec;17(8):515-521
pubmed: 27720383
EuroIntervention. 2020 Sep 18;16(7):603-612
pubmed: 32588821
EuroIntervention. 2014 Sep;10(5):545-60
pubmed: 25256198
Circ Cardiovasc Interv. 2020 Mar;13(3):e008325
pubmed: 32102566
EuroIntervention. 2015;11 Suppl V:V86-90
pubmed: 25983180
Int J Cardiol. 2019 Oct 1;292:95-97
pubmed: 31130279
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Catheter Cardiovasc Interv. 2008 Feb 1;71(2):175-83
pubmed: 17985377
EuroIntervention. 2010 May;6(1):34-8
pubmed: 20542795
Korean Circ J. 2019 Jun;49(6):485-494
pubmed: 30891962
Int J Cardiovasc Imaging. 2019 Jun;35(6):981-990
pubmed: 30887408
EuroIntervention. 2008 Jan;3(4):490-8
pubmed: 19736093
JACC Cardiovasc Interv. 2015 Aug 24;8(10):1297-1307
pubmed: 26315732
J Gen Physiol. 1926 Jul 20;9(6):835-41
pubmed: 19872299
Cardiovasc Revasc Med. 2017 Jun;18(4):233-240
pubmed: 28108202
Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E437-45
pubmed: 23441082
Circulation. 2011 Jan 4;123(1):79-86
pubmed: 21173348
Circ Cardiovasc Interv. 2017 Oct;10(10):
pubmed: 29038225
JACC Cardiovasc Interv. 2012 Aug;5(8):803-11
pubmed: 22917451
Catheter Cardiovasc Interv. 2020 Jul;96(1):31-39
pubmed: 32087046
JACC Cardiovasc Interv. 2016 Sep 26;9(18):1861-78
pubmed: 27659563

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH